{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:52:27Z","timestamp":1792788747856,"version":"4.5.0"},"reference-count":38,"publisher":"Informa UK Limited","issue":"35","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.2217\/fon-2023-0228","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T06:51:31Z","timestamp":1690872691000},"page":"2349-2359","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":60,"title":["TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6421-7602","authenticated-orcid":false,"given":"Rebecca A","family":"Dent","sequence":"first","affiliation":[{"name":"National Cancer Center Singapore,\rSingapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Cescon","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre\/UHN, Toronto,\rON,\rCanada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bachelot","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard,\rLyon,\rFrance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hae","family":"Jung","sequence":"additional","affiliation":[{"name":"Asan Medical Center,University of Ulsan College of Medicine,\rSeoul,\rKorea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ming","family":"Shao","sequence":"additional","affiliation":[{"name":"Fudan University Cancer Institute,\rShanghai,\rChina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehira","family":"Saji","sequence":"additional","affiliation":[{"name":"Fukushima Medical University Hospital,\rFukushima,\rJapan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany A","family":"Traina","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center,\rNew York,\rNY,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Vukovic","sequence":"additional","affiliation":[{"name":"AstraZeneca,\rCambridge,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlington","family":"Mapiye","sequence":"additional","affiliation":[{"name":"AstraZeneca,\rCambridge,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah J","family":"Maxwell","sequence":"additional","affiliation":[{"name":"AstraZeneca,Gaithersburg,\rMD,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schmid","sequence":"additional","affiliation":[{"name":"Barts Cancer Institute,\rLondon,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[{"name":"International Breast Cancer Center,Pangaea Oncology IBCC,\rBarcelona,\rSpain"},{"name":"Medica Scientia Innovation Research (MedSIR),\rBarcelona,\rSpain"},{"name":"Universidad Europea de Madrid, Faculty of Biomedical & Health Sciences,Department of Medicine,\rMadrid,\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,8]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5306"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20190288"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.66"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0902-SA"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01374"},{"key":"e_1_3_5_9_1","unstructured":"European Society for Medical Oncology (ESMO) . ESMO Metastatic Breast Cancer Living Guidelines. https:\/\/www.esmo.org\/living-guidelines\/esmo-metastatic-breast-cancer-living-guidelines\/triple-negative-breast-cancer (Accessed 26July2022)."},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001558"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/417673"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.1005"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2011.12.001"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.574813"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2560"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2008-6"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2017.562"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-0824-0"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw203"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0206"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep33658"},{"issue":"2","key":"e_1_3_5_27_1","first-page":"759","article-title":"TROP2 is a potential biomarker for the promotion of EMT in human breast cancer","volume":"40","author":"Zhao W","year":"2018","unstructured":"Zhao W , KuaiX, ZhouXet al. TROP2 is a potential biomarker for the promotion of EMT in human breast cancer. Oncol. Rep.40(2), 759\u2013766 (2018).","journal-title":"Oncol. Rep."},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c18-00744"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/antib10020020"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081707"},{"key":"e_1_3_5_34_1","volume-title":"Oral presentation at the World Conference on Lung Cancer (WCLC).","author":"Heist RS","year":"2019","unstructured":"Heist RS , SandsJM, ShimizuTet al. First-in-human phase I study of DS-1062a (TROP2 antibody-drug conjugate) in patients with advanced non-small-cell lung cancer. Presented at: Oral presentation at the World Conference on Lung Cancer (WCLC).Barcelona, Spain, 7\u201310 September 2019."},{"key":"e_1_3_5_35_1","volume-title":"European Society for Medical Oncology (ESMO). Paris.","author":"Bardia A","year":"2022","unstructured":"Bardia A , KalinskyK, TsurutaniJet al. Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, vs investigator\u2019s choice of chemotherapy (ICC) in previously treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR+\/HER2-) breast cancer: TROPION-Breast01. Program and Abstracts of: European Society for Medical Oncology (ESMO). Paris.France, 9\u201313 September 2022 (Poster 274TiP)."},{"key":"e_1_3_5_36_1","volume-title":"San Antonio Breast Cancer Symposium (SABCS).","author":"Bardia A","year":"2022","unstructured":"Bardia A , KropI, Meric-BernstamFet al. Datopotamab deruxtecan (Dato-DXd) in advanced triple-negative breast cancer (TNBC): updated results from the phase I TROPION-PanTumor01 study. Presented at: San Antonio Breast Cancer Symposium (SABCS).San Antonio, TX, USA, 6\u201310 December 2022 (Poster P6-10\u201303)."},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.118"},{"key":"e_1_3_5_38_1","volume-title":"San Antonio Breast Cancer Symposium (SABCS).","author":"Krop I","year":"2021","unstructured":"Krop I , JuricD, ShimizuTet al. Datopotomab deruxtecan (Dato-DXd) in advanced\/metstatic HER2 negative breast cancer: triple negative breast cancer results from the phase I TROPION-PanTumor01 study. Presented at: San Antonio Breast Cancer Symposium (SABCS).San Antonio, TX, USA, 7\u201310 December 2021 (Oral GS01-05)."},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.03.185"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0904-SA"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-0228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:44:55Z","timestamp":1719110695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-0228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":38,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.2217\/fon-2023-0228"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-0228","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}